Allecra Therapeutics
Weil Am Rhein
About Allecra Therapeutics
Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel ╬▓-lactamase inhibitor in Phase 2 clinical development. By inhibiting ╬▓-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $44.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2016)
- Website: allecra.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/allecra-therapeutics-83345 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.